The Non-psychoactive Cannabis Constituent Cannabidiol is an Orally Effective Therapeutic Agent in Rat Chronic Inflammatory and Neuropathic Pain.
From: Department of Biotechnology and Bioscience, University of Milano-Bicocca, piazza della Scienza 2, 20126 Milano, Italy. barbara.costa@unimib.it
European journal of pharmacology
- Publish Date: Feb 2007
- ISSN: 0014-2999
- Volume: 556
- Issue: 1-3
- Pages: 75-83
- Medium: Print
- Language: English
- Citation (JAMA): Costa Barbara, Trovato Anna Elisa, Comelli Francesca, et al. The Non-psychoactive Cannabis Constituent Cannabidiol is an Orally Effective Therapeutic Agent in Rat Chronic Inflammatory and Neuropathic Pain.. Eur. J. Pharmacol. Feb 2007;556:75-83
Abstract
Cannabidiol, the major psycho-inactive component of cannabis, has substantial anti-inflammatory and immunomodulatory effects. This study investigated its therapeutic potential on neuropathic (sciatic nerve chronic constriction) and inflammatory pain (complete Freund’s adjuvant intraplantar injection) in rats. In both models, daily oral treatment with cannabidiol (2.5-20 mg/kg to neuropathic and 20 mg/kg to adjuvant-injected rats) from day 7 to day 14 after the injury, or intraplantar injection, reduced hyperalgesia to thermal and mechanical stimuli. In the neuropathic animals, the anti-hyperalgesic effect of cannabidiol (20 mg/kg) was prevented by the vanilloid antagonist capsazepine (10 mg/kg, i.p.), but not by cannabinoid receptor antagonists. Cannabidiol’s activity was associated with a reduction in the content of several mediators, such as prostaglandin E(2) (PGE(2)), lipid peroxide and nitric oxide (NO), and in the over-activity of glutathione-related enzymes. Cannabidiol only reduced the over-expression of constitutive endothelial NO synthase (NOS), without significantly affecting the inducible form (iNOS) in inflamed paw tissues. Cannabidiol had no effect on neuronal and iNOS isoforms in injured sciatic nerve. The compound’s efficacy on neuropathic pain was not accompanied by any reduction in nuclear factor-kappaB (NF-kappaB) activation and tumor necrosis factor alpha (TNFalpha) content. The results indicate a potential for therapeutic use of cannabidiol in chronic painful states.
Mesh Headings (Keywords): Administration, Oral, Animals, Cannabidiol, Cannabis, Capsaicin, Chronic Disease, Dinoprostone, Freund’s Adjuvant, Hyperalgesia, Inflammation, Lipid Peroxides, Male, NF-kappa B, Nitric Oxide, Nitric Oxide Synthase, Pain, Pain Measurement, Rats, Rats, Wistar, Receptors, Cannabinoid, Sciatic Neuropathy, Tumor Necrosis Factor-alpha
Check for Full Text / PubMed Unique Identifier (PMID): 17157290
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.